Barclays’s Amicus Therapeutics FOLD Stock Holding History

Barclays’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-32,400	Closed	-$186K	–	5565
2025 Q2	$186K	Hold	32,400	–	–	﹤0.01%	4329
2025 Q1	$264K	Buy	+32,400	New	+$300K	﹤0.01%	3896
2024 Q3	–	Sell	-114,000	Closed	-$1.13M	–	5347
2024 Q2	$1.13M	Buy	+114,000	New	+$1.17M	﹤0.01%	2529
2021 Q2	–	Sell	-300	Closed	-$3K	–	4934
2021 Q1	$3K	Buy	+300	New	+$4.64K	﹤0.01%	4523
2019 Q3	–	Sell	-89,000	Closed	-$1.11M	–	6830
2019 Q2	$1.11M	Buy	+89,000	New	+$1.13M	﹤0.01%	3574
2018 Q3	–	Sell	-8,500	Closed	-$133K	–	7212
2018 Q2	$133K	Buy	+8,500	New	+$128K	﹤0.01%	5056
2017 Q4	–	Sell	-115,400	Closed	-$1.74M	–	6972
2017 Q3	$1.74M	Buy	+115,400	New	+$1.53M	﹤0.01%	2485
2017 Q1	–	Sell	-67,500	Closed	-$335K	–	6815
2016 Q4	$335K	Hold	67,500	–	–	﹤0.01%	3734
2016 Q3	$500K	Buy	+67,500	New	+$456K	﹤0.01%	3222

Other funds holding FOLD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Barclays's FOLD Position: Q1 2026 in Review

Barclays increased its Amicus Therapeutics (FOLD) stake by 18% in Q1 2026, buying an estimated $2.92M and bringing the position to 1,338,482 shares worth $19.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1122.

Barclays first reported a position in FOLD in Q2 2013 and has held it in 51 quarters since. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

Barclays held 1,338,482 shares of Amicus Therapeutics worth $19.4M as of Q1 2026.
Barclays bought 203,843 Amicus Therapeutics shares in Q1 2026, an estimated $2.92M.
Amicus Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #1122 holding.
Barclays first reported a position in Amicus Therapeutics in Q2 2013 and has held it in 51 quarters since.
298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.